Onkologie. 2026:20(3):155-162 | DOI: 10.36290/xon.2026.029

Metastatic hormone-sensitive prostate cancer, new treatments

Jan Dvořák, Renata Soumarová, Martin Palkovský
Onkologická klinika, FNKV a 3. LF UK, Praha

Prostate cancer is one of the most common malignancies in men. In recent years, it has significantly expanded to include biological, or targeted therapy. Biological treatment includes mainly drugs that interfere with androgen signaling, therapy focused on specific molecular pathways and features. The aim of this article is to present recent developments in metastatic hormone-sensitive prostate cancer and to indicate possible future directions of development.

Keywords: prostate cancer, androgen receptor, metastatic hormone-sensitive prostate cancer, androgen receptor signaling pathway inhibitors (ARPI), PARP inhibitors, AKT inhibitors, PTEN loss, CDK4/6 inhibitors, EZH2 inhibitors, immunotherapy, chemotherapy, radioligand therapy.

Accepted: June 15, 2026; Published: July 1, 2026  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Dvořák J, Soumarová R, Palkovský M. Metastatic hormone-sensitive prostate cancer, new treatments. Onkologie. 2026;20(3):155-162. doi: 10.36290/xon.2026.029.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Purchase PDF - 60 CZK (2.5 EUR)
    will be unlocked 1.7.2027

    References

    1. Lowrance WT, Breau RH, Chou R, et al. Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART I. J. Urol. 2021;205:14-21. Go to original source...
    2. Sweeney ChJ, Chen YH, Carducci M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. New England Journal of Medicine. 2015;373(8):737-746. doi: 10.1056/NEJMoa1503747. Go to original source...
    3. Ranasinghe WK, Bolton D, Lawrentschuk N, et al. Cytoreductive prostatectomy in metastatic prostate cancer: what the individual trials are hoping to answer. BJU International. 2020;125(6):792-800. doi: 10.1111/bju.15030. Go to original source...
    4. Sooriakumaran P, Wilson C, Rombach I, et al. Feasibility and safety of radical prostatectomy for oligo-metastatic prostate cancer: the testing radical prostatectomy in men with prostate cancer and oligo-metastases to the bone (TRoMbone) trial. BJU international. 2022;130.1:43-53. Go to original source...
    5. Burdett S, Boeve LMS, Ingleby FC, et al. Prostate radiotherapy for metastatic hormone-sensitive prostate cancer: a STOPCAP systematic review and meta-analysis. European Urology. 2019;76(1):115-124. doi: 10.1016/j.eururo.2019.02.003. Go to original source... Go to PubMed...
    6. Clarke NW, Ali A, Ingleby FC, et al. Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial. Annals of Oncology. 2019;30(12):1992-2003. doi: 10.1093/annonc/mdz398. Go to original source... Go to PubMed...
    7. Fizazi K, Tran N, Fein L, et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. The Lancet Oncology. 2019;20(5):686-700. doi: 10.1016/S1470-2045(19)30082-8. Go to original source...
    8. Armstrong AJ, Szmulewitz RZ, Petrylak DP, et al. ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. Journal of Clinical Oncology. 2019;37(32):2974-2986. doi: 10.1200/JCO.19.00799. Go to original source... Go to PubMed...
    9. Sweeney ChJ, Davis ID, Taplin ME, et al. Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial. The Lancet Oncology. 2023;24(4):323-334. doi: 10.1016/S1470-2045(23)00040-7. Go to original source...
    10. Kim N. Chi, Fred Saad, Karim Fizazi, et al. Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study. Journal of Clinical Oncology. 2021;39(20):2294-2303. doi: 10.1200/JCO.20.03505. Go to original source...
    11. SAAD F, Shore N, Fizazi K, et al. Darolutamide in combination with androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer from the phase III ARANOTE trial. Journal of Clinical Oncology. 2024;42(36):4271-4281. Go to original source...
    12. Smith MR, Hussain M, Saad F, et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. New England Journal of Medicine. 2022;386(12):1132-1142. doi: 10.1056/NEJMoa2119115. Go to original source... Go to PubMed...
    13. Fizazi K, Foulon S, Carles J, et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2×2 factorial design. The Lancet. 2022;399(10336):1695-1707. doi: 10.1016/S0140-6736(21)02282-4. Go to original source...
    14. Hamid AA, Huang HC, Wang V, et al. Transcriptional profiling of primary prostate tumor in metastatic hormone-sensitive prostate cancer and association with clinical outcomes: correlative analysis of the E3805 CHAARTED trial. Ann Oncol. 2021;32(9):1157-1166. Go to original source...
    15. Swami U, Graf RP, Nussenzveig RH, et al. SPOP mutations as a predictive biomarker for androgen receptor axis-targeted therapy in de novo metastatic castration-sensitive prostate cancer. Clin Cancer Res. 2022;28(22):4917-4925. Go to original source...
    16. Gu W, Han W, Luo H, et al. Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial. The Lancet Oncology. 2022;231(10):1249-1260. Go to original source...
    17. Comparing a 6-month vs. Long-term Course of Rezvilutamide With ADT Plus Chemotherapy in mHSPC. Available from: https://clinicaltrials.gov/study/NCT05956639?term=Comparing%20a%206-month%20vs%20Long-term%20Course%20
    18. Lonergan PE, Tindall DJ. Androgen receptor signaling in prostate cancer development and progression. Journal of carcinogenesis. 2011;10:20. Go to original source...
    19. Culig Z. Targeting the androgen receptor in prostate cancer. Expert opinion on pharmacotherapy. 2014;15(10):1427-1437. Go to original source...
    20. Sakellakis M. Niclosamide in prostate cancer: An inhibitor of AR-V7, a mitochondrial uncoupler, or more? Cancer Treatment and Research Communications. 2023;35:100685. Go to original source...
    21. Raith F, O'Donovan DH, Lemos C, et al. Addressing the reciprocal crosstalk between the AR and the PI3K/AKT/mTOR signaling pathways for prostate cancer treatment. International Journal of Molecular Sciences. 2023;24(3):2289. doi: 10.3390/ijms24032289. Go to original source... Go to PubMed...
    22. Attard G, Agarwal N, Graff JN, et al. Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial. Nature Medicine. 2025;31(12):4109-4118. doi: 10.1038/s41591-025-03961-8. Go to original source... Go to PubMed...
    23. Rathkopf DE, Agarwal N, Graff JN, et al. LBA91 Patient-reported outcomes (PROs) from AMPLITUDE, a randomized placebo-controlled phase III trial of niraparib (NIRA) and abiraterone acetate (AA) plus prednisone (P) in metastatic hormone-sensitive prostate cancer (mHSPC) with homologous recombination repair mutations (HRRm). Annals of Oncology. 2025;36:S1747-S1748. Go to original source...
    24. Agarwal N, Saad F, Azad AA, et al. TALAPRO-3 clinical trial protocol: phase III study of talazoparib plus enzalutamide in metastatic castration-sensitive prostate cancer. Future Oncology. 2024;20(9):493-505. doi: 10.2217/fon-2023-0526. Go to original source... Go to PubMed...
    25. Azad AA, Agarwal N, Armstrong AJ, et al. Phase III, double-blind, placebo-controlled, 2-cohort, randomized study of saruparib (AZD5305) in combination with androgen receptor pathway inhibitors in patients with metastatic hormone-sensitive prostate cancer with and without homologous recombination repair mutation (EvoPAR-Prostate01). Journal of Clinical Oncology. 2025;43(5_suppl):TPS279. doi: 10.1200/JCO.2025.43.5_suppl.TPS279. Go to original source...
    26. Fizazi K, Clarke NW, De Santis M, et al. Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study. Annals of Oncology. 2026;37(1):53-68. doi: 10.1016/j.annonc.2025.10.004. Go to original source... Go to PubMed...
    27. Agarwal N, Chi K, Sartor O, et al. A signal-finding study of abemaciclib in heavily pretreated patients with metastatic castration-resistant prostate cancer: results from CYCLONE 1. Clinical Cancer Research. 2024;30(11):2377-2383. doi: 10.1158/1078-0432.CCR-23-3253. Go to original source...
    28. Gebrael G, Ostrowski M, Agarwal N. Metastatic prostate cancer: Clinical trials to watch. Med. 2025;6(11):100927. doi: 10.1016/j.medj.2025.100927. Go to original source... Go to PubMed...
    29. Available from: https://clinicaltrials.gov/study/NCT07028853.
    30. Agarwal N, Schweizer MT, Castro E, et al. Mevrometostat (PF-06821497) in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with abiraterone acetate: The phase 3, randomized MEVPRO-1 study. Urologic Oncology: Seminars and Original Investigations. Elsevier; 2025:2-3. Go to original source...
    31. Schweizer MT, Agarwal N, Castro E, et al. Mevrometostat (PF-06821497) in combination with enzalutamide for androgen receptor pathway inhibitor (ARPI)-naïve patients with metastatic castration-resistant prostate cancer (mCRPC): The phase 3, randomized MEVPRO-2 trial. J. Clin. Oncol. 2025;43. Go to original source...
    32. Gratzke C, Özgüroğlu M, Peer A, et al. Pembrolizumab plus enzalutamide and androgen deprivation therapy versus placebo plus enzalutamide and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: the randomized, double-blind, phase III KEYNOTE-991 study. Annals of Oncology. 2025;36(8):964-975. doi: 10.1016/j.annonc.2025.05.008. Go to original source... Go to PubMed...
    33. Tagawa ST, Sartor O, Piulats J, et al. LBA6 Phase III trial of [177Lu]Lu-PSMA-617 combined with ADT + ARPI in patients with PSMA-positive metastatic hormone-sensitive prostate cancer (PSMAddition). Annals of Oncology. 36;S1627-S1628. Go to original source...
    34. Grimm MO, von Amsberg G, Heers H, et al. 3-weekly docetaxel 75 mg/m<sup>2</sup> vs 2-weekly docetaxel 50 mg/m<sup>2</sup> in combination with darolutamide + ADT in patients with metastatic hormone-sensitive prostate cancer: Results from the randomised phase III ARASAFE trial. Annals of Oncology. 2025;36(Suppl S):S1748. doi: 10.1016/j.annonc.2025.09.108. Go to original source...
    35. Ong M, Agarwal N, Armstrong AJ, et al. TRIPLE-SWITCH (SWOG/CCTG-PR26): A randomized phase III clinical trial for the addition of docetaxel to androgen receptor pathway inhibitors in patients with metastatic castration sensitive prostate cancer (mCSPC) and suboptimal PSA response (NCT06592924). J. Clin. Oncol. 2025;(43):16. Go to original source...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.